⚡️ Immunotherapy transformed cancer care, but not all respond. This review examines current successes, challenges, and future prospects when combining radiotherapy with immunotherapy #Immunotherapy #radiotherapy redjournal.org/article/S0360-…

🌟Spotlight on #Immunotherapy: Discover the visionary insights of Eric Deutsch and Udo Gaipl, course directors of our upcoming course. 💡Explore the intersection of RT delving into novel therapeutic approaches: bit.ly/3TUQAso 📅Join them at the Course on 3-5 March 2024.

Time to rebrand radiotherapy as radiatumumab and re publish all our OS, PFS, and safety profile data U.S. FDA President Donald J. Trump #radonc

Where is RT 👀? Despite overall dearth of RCTs comparing local modalities in HCC, we have randomized studies in support of RT across the disease spectrum: Early/Intermediate stage: Loma Linda trial - RT (protons) vs. TACE: similar OS, RT better PFS & local control

Largest study for 1-2 macromets in both mastectomy and BCS showing no difference in DFS and axillary recurrence with ALND vs. RT ( most got regional nodal RT ) #bcsm ⁦Chirag Shah⁩ ⁦Erin Gillespie, MD MPH⁩ ⁦ACROresident⁩ ⁦ARRO⁩ nejm.org/doi/full/10.10…

Durvalumab becomes the 1st and only immunotherapy to significantly enhance OS and PFS in limited-stage small cell #LungCancer 🫁patients following concurrent chemoradiotherapy☢️ according to ADRIATIC 🌊

The trial for small cell lung cancer Adriatic Durvalumab consolidation post CTRT for Limited stage SCLC. HR PFS -16.6 vs 9.2 months - HR 0.76 OS- 55. 9 vs 33.4 HR- 0.73 Toxicity - Same in both arms -24.3 vs 24.2 % - pneumonits 38 % vs 30 % Cross over - we need to check

The beautiful Institut Jules Bordet Instituut family is reunited in Barcelona for the European Society of Medical Oncology annual meeting 2024 #ESMO24! We come back with the updates in oncology and lots of new projects to help our patients 💥🎗

⏳Can’t wait for the eBC proffered session about to start at 10:15 in #ESMO24 Barcelona Auditorium! Alex De Caluwe from Institut Jules Bordet Instituut will be presenting primary results of Neo-CheckRay trial. ➡️ Intriguing results on SBRT + Immunotherapy in neoadjuvant HR+ eBC! OncoAlert

NEOCheck-Ray: does adding #durvalumab and SBRT to neoadjuvant chemotherapy improves pCR in Lum B #ebc ? Alex De Caluwe Institut Jules Bordet Instituut OncoAlert  #ESMO24 #ESMOAmbassadors

At #ESMO24 Alex De Caluwe presents results of NeoCheckRay, evaluating SBRT⚡️+/- durva +/- oleclumab combined with NACT in Luminal B EBC Promising activity of RT-IO combination in ⬆️pCR/RCB 0-1 in these cold tumors, especially in the subgroup with PD-L1 tumors 🥶➡️🥵 OncoAlert

#ESMO24 proffered eBC session Neo-CheckRay trial presented by Alex De Caluwe demonstrated numerically ⬆️ RCB0/1 with Durvalumab + Oleclumab + SBRT during neoadjuvant tp in high-risk, HR+ eBC. 🔎 Impressive responses with ICIs + SBRT in PDL1 neg disease! OncoAlert Institut Jules Bordet Instituut

Randomized phase 2 trial evaluating SBRT to the Primary Breast Cancer +/- Durvalumab +/- Oleclumab combined with Neoadjuvant Chemotherapy for Early-Stage High Risk ER+/HER2- 👉 high rates of pCR especially in PD-L1 neg pts

Congratulations Alex De Caluwe and Bordet team for this timely study focus on crucial topic RT-drug synergy Primary endpoint results NEO-CHECKRAY phase 2 trial #ESMO24 OncoAlert #OncoAlert #radonc #medonc

Neo-CheckRay presented by Alex De Caluwe Ph2 II trial in early LumB BC, exploring NACT + SBRT + IO (anti-PD-L1, anti-CD73) The addition of IO to NACT+SBRT numerically improved RCB0/1 rates (38% vs 51%, P = 0.2) Incredibly proud to be part of this effort! OncoAlert

Very interesting results by PD-L1 status Unlike Keynote756 and Checkmate7FL, which showed higher benefit of IO in PD-L1+, Neo-CheckRay found greater benefit in PD-L1- pts, suggesting SBRT may be a particularly effective IO priming strategy for this population OncoAlert

👏Fascinating results on RT + IO in breast cancer presented by my good friend Alex De Caluwe at this year's #ESMO2024 - makes you dream about a similar concept in #GIonc 🤔

October is #BreastCancerAwarenessMonth 📣 Check out this interview from #ESMO2024 w/ Alex De Caluwe | Neo-CheckRay: #chemotherapy and SBRT with #durvalumab and #oleclumab in #ER+/#HER2- #breastcancer 🎥 👉 vjoncology.com/video/3trnjmui…

🔬 The Neo-CheckRay trial explored pre-op immune-modulating SBRT (8 Gy x 3) + immunotherapy in luminal B breast cancer, sparing tumor-draining lymph nodes to avoid immunosuppression. Feasible, but more research needed! thegreenjournal.com/article/S0167-… #BreastCancer #RadiationOncology

Investigator-initiated study sponsored by Institut Jules Bordet Instituut and chaired by Alex De Caluwe and Laurence Buisseret. Primary endpoint results presented at #ESMO24 oncologypro.esmo.org/meeting-resour…